Asked by: Jeremy Hunt (Conservative - Godalming and Ash)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) prioritise research into pancreatic cancer and (b) encourage innovations in earlier diagnosis.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department invests over £1.6 billion each year on research through the National Institute for Health and Care Research (NIHR), and in 2024/25, spent £141.6 million on cancer research, signalling its high priority. This includes studies that focus specifically on pancreatic cancer as well as studies that are relevant to or include pancreatic cancer. For example, between the 2020/21 to 2024/25 financial years, the NIHR committed £1.5 million to specific pancreatic cancer studies.
One instance of this is ongoing research funded by the NIHR which aims into improve the early diagnosis of pancreatic cancer by utilising artificial intelligence as well as reducing instances of missed cancer.
The NIHR’s wider investments in research infrastructure, including facilities, services, and the research workforce, supported the delivery of 160 pancreatic cancer research studies and enabled over 8,200 people to participate in potentially life-changing research during this time period. This includes support for the PemOla trial, which is the first to explore using precision immunotherapies to treat pancreatic cancer.
The Office for Life Sciences’ Cancer Healthcare Goals programme aims to maximise and direct global industrial investment for the development and acceleration of new cancer diagnostic and therapeutic technologies and devices in the United Kingdom through: providing research investments to support the development of innovations in the early stages of the development pathway and; supporting industry to accelerate cancer diagnostic and therapeutic technologies and devices in the latter stages of development into the National Health Service.
The programme launched the £10.9 million NIHR i4i Cancer Healthcare Goals: Early Cancer Diagnosis Clinical Validation and Evaluation Call. This has funded six projects which are developing breakthrough technologies that can increase the proportion of cancers which are detected earlier in the disease course and/or target health inequalities in cancer diagnosis.
This includes the miONCO-Dx multi-cancer early detection test, developed by XGenera, which can identify 12 of the most lethal and common cancers, including pancreatic cancer, at even the earliest stages from just 100 microlitres of blood. This technology is currently testing the diagnostic test accuracy on over 20,000 patient samples with promising early results.
The NIHR continues to encourage and welcome high quality funding applications into pancreatic cancer.
Asked by: Jeremy Hunt (Conservative - Godalming and Ash)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to improve access to clinical trials for patients with pancreatic cancer.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is committed to ensuring that all patients, including those with pancreatic cancer, have access to cutting-edge clinical trials and innovative, lifesaving treatments.
The Department funds research and research infrastructure through the National Institute for Health and Care Research (NIHR), which supports National Health Service patients, the public, and NHS organisations across England to participate in high-quality research, including clinical trials into cancers.
NIHR provides an online service called 'Be Part of Research', which promotes participation in health and social care research by allowing users to search for relevant studies and register their interest.
The forthcoming National Cancer Plan will include further details on how we will improve outcomes for cancer patients across the country. It will ensure that more patients have access to the latest treatments and technology, and to clinical trials.
The Government also supports the Rare Cancers Private Members Bill. The bill will make it easier for clinical trials, on for example pancreatic cancer, to take place in England, by ensuring the patient population can be more easily contacted by researchers.